凯信远达制药（CASI Pharmaceuticals）近日提交至美国证券交易委员会（SEC）的文件披露，公司董事会已正式任命何伟武（Wei-Wu He）担任执行主席一职，该项人事变动自2024年2月17日起正式生效。
凯信远达制药（CASI Pharmaceuticals）近日提交至美国证券交易委员会（SEC）的文件披露，公司董事会已正式任命何伟武（Wei-Wu He）担任执行主席一职，该项人事变动自2024年2月17日起正式生效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.